Literature DB >> 20555058

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

L Crinò1, W Weder, J van Meerbeeck, E Felip.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20555058     DOI： 10.1093/annonc/mdq207

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  184 in total

Review 1.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer.

Authors:  Jan P van Meerbeeck; Halil Sirimsi
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  Pros: long-term CT scan follow-up should be the standard of care in patients who are curatively treated for an early-stage non-small cell lung cancer.

Authors:  Waël C Hanna
Journal:  Transl Lung Cancer Res       Date:  2015-08

4.  Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up.

Authors:  Fabrice Denis; Louise Viger; Alexandre Charron; Eric Voog; Christophe Letellier
Journal:  Support Care Cancer       Date:  2013-09-01       Impact factor: 3.603

Review 5.  A review of clinical practice guidelines for lung cancer.

Authors:  Jutta J von Dincklage; David Ball; Gerard A Silvestri
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

6.  Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Authors:  Ignacio I Wistuba; Carmen Behrens; Francesca Lombardi; Susanne Wagner; Junya Fujimoto; M Gabriela Raso; Lorenzo Spaggiari; Domenico Galetta; Robyn Riley; Elisha Hughes; Julia Reid; Zaina Sangale; Steven G Swisher; Neda Kalhor; Cesar A Moran; Alexander Gutin; Jerry S Lanchbury; Massimo Barberis; Edward S Kim
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

7.  Quality gaps and comparative effectiveness in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

8.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

9.  Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer.

Authors:  Jianwei Gao; Lei Li; Xia Liu; Rui Guo; Bin Zhao
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

10.  Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer.

Authors:  Zekai Shu; Baiqiang Dong; Lei Shi; Wei Shen; Qingqing Hang; Jin Wang; Yuanyuan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-02-24       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.